苑东生物(688513.SH):EP-0210单抗注射液I期临床试验完成首例受试者给药

智通财经
Feb 09

智通财经APP讯,苑东生物(688513.SH)发布公告,公司全资子公司成都优洛生物科技有限公司自主研发的1类生物药EP-0210单抗注射液正在开展用于治疗炎症性肠病的I期临床试验,于近日完成首例受试者给药。

EP-0210单抗注射液是一款靶向人肿瘤坏死因子样配体1A(TNF-like ligand1A,TL1A)的人源化IgG1单克隆抗体药物,拟定适应症为炎症性肠病,其作用机制是通过高效结合人TL1A,阻止TL1A介导的促炎症信号通路,从而发挥治疗炎症性肠病的作用。临床前研究表明,EP-0210单抗注射液药效作用机制明确,在多种炎症性肠病体内模型中药效显著,具有良好的安全性和有效性;其在靶点活性、体内药效等方面优于国外同靶点竞品RVT-3101,有望为炎症性肠病患者带来安全有效的更多选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10